Hidden in Plain Sight: Identifying Women Living in the United States Who Could Benefit From HIV Preexposure Prophylaxis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31549150.
- Also identified by DOI 10.1093/infdis/jiz416 and PMC identifier 7529034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtricitabine is an effective means of decreasing human immunodeficiency virus (HIV) acquisition among women. However, few women are prescribed and are taking PrEP. This article offers perspectives on barriers to use and strategies to increase uptake among women.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Pre-Exposure Prophylaxis